跳至主要内容
临床试验/NCT06379282
NCT06379282招募中不适用

Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia

University of Surrey2 个研究点 分布在 1 个国家目标入组 132 人开始时间: 2022年10月14日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
132
试验地点
2
主要终点
Change from baseline in absolute number of CD19+/CD5+ CLL cells at week 12

研究概览

简要总结

This randomised control clinical trial aims to investigate the effects of exercise training and diet on physical and functional fitness and immunological and metabolic changes in adults with chronic lymphocytic leukaemia. Investigators will randomise participants to either 12 weeks of supervised/semi-supervised exercise only, exercise + nutritional guidance, or no exercise.

详细描述

This study aims to perform a randomised control trial of exercise or exercise plus nutritional guidance on the physiological and immunological health of adults diagnosed with chronic lymphocytic leukaemia (CLL). Recruited participants will be randomised to either 12 weeks of an exercise-only program, an exercise-plus nutritional guidance program or a no-exercise control group. Fasting blood samples collected at Baseline and 12 weeks will measure absolute CLL cell counts, immune function, and inflammatory and metabolic biomarkers. A series of physical fitness assessments will be assessed at baseline and 12 weeks to determine physiologic reserve and resilience against external stressors. Additionally, participants will be asked to return 12 weeks after completing the intervention to assess the legacy effects of the intervention on the same physiological and blood-based biomarkers of health.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed diagnosis of CLL (including small lymphocytic leukaemia) as per the International Workshop on CLL Guidelines.
  • Male or female ≥ 18 years of age
  • Able to walk on a treadmill or cycle on an ergometer
  • Pass the Physical Activity Readiness Questionnaires (PAR-Q and PAR-Q+)

排除标准

  • Corticosteroid therapy initiated less than 7 days before study entry. Prednisone 10mg or less or equivalent is allowed. Topical or inhaled corticosteroids are permitted.
  • Secondary malignancy within 3 years of study enrollment requiring intervention except for adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in situ of the cervix, superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localised prostate cancer and PSA stable.
  • Absolute contraindications to exercise: Recent (<6 months) acute cardiac event unstable angina, uncontrolled dysrhythmias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspected or known dissecting aneurism and acute systemic infection.
  • Significant orthopaedic limitations, musculoskeletal disease and/or injury. Due to the nature of the study, persons with known joint, muscle or other orthopaedic limitations that restrict physical activity may be excluded.
  • Type I diabetes mellitus or uncontrolled Type II diabetes mellitus, or chronic obstructive pulmonary disease
  • Uncontrolled blood pressure (≥180/90) at rest
  • Known concurrent HIV, Hepatitis B or Hepatitis C
  • Unable to comply with other study requirements

结局指标

主要结局

Change from baseline in absolute number of CD19+/CD5+ CLL cells at week 12

时间窗: Baseline and 12 weeks

A blood sample will be taken and assessed for CD19+/CD5+ CLL frequency using flow cytometry and total lymphocyte counts to determine the absolute number of CLL cells in x10\^9/L

Change from baseline in cardiorespiratory fitness (CRF: VO2peak) at week 12

时间窗: Baseline and 12 weeks

Cardiopulmonary exercise testing will be conducted to assess changes in fitness

次要结局

  • Muscle Strength and Endurance(Baseline and 12 weeks)
  • Frailty(Baseline and 12 weeks)
  • Change in systemic and cellular bioenergetics(Baseline and 12 weeks)
  • Change in Quality of Life using the EORCT-QLQ-C30(Baseline and 12 weeks)
  • Change in B-CLL Cell Function(Baseline and 12 weeks)
  • Muscle Health(Baseline and 12 weeks)
  • Change in muscle oxygen metabolism during a single bout of exercise(Baseline and 12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

David Bartlett

Senior Lecturer

University of Surrey

研究点 (2)

Loading locations...

相似试验

Investigating the Role of Energy Balance... | 临床试验